Poster

Characterization and Drugs Screening in Human Dermal Fibroblasts Derived From Patient With Amiotrophic Lateral Sclerosis



Sánchez, J. A. (1); Suárez, A.(1,*)

(1) Departamento de Fisiología, Anatomía y Biología Celular. Centro Andaluz de Biología del Desarrollo (CABD), Carretera de Utrera Km 1 41013 Sevilla

Keywords: Amiotrophic Lateral Sclerosis; Human Dermal Fibroblast; Iron Accumulation.

ABSTRACT

Motivation: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease caused by the loss of motor neurons. Though currently we unknow its etiology, there are several alterations related to its physiopathology, such as mutation in Superoxide dismutase-1 (SOD-1), an enzyme which prevents free radical production, and intracellular non-avaliable iron accumulation, both alterations have been observed in the patient. The mutated form of this enzyme tends to form fibrillar aggregates on the cytoplasm. In this way, the research line have two parts: the molecular characterization of the disease, and the elimination or reduction of intracellular iron accumulation and the reestablishment of modified protein levels. Treatments screening allows to increase patient's survival due to we use commercialized compounds, with this approximation we can skip long proccess of drugs commercialization.

Methods: Human Dermal Fibroblast (HDF) primary cultures with and without pathological background are used. Iron accumulation in this cultures is observed by Prussian Blue technique. Expression protein levels are measured by Western Blotting, TransferBlot, InmmunoBlot and ChemicDoc developing. Quantifications were calculated with ImageJ software.

Preliminar Results: We observed differences in the expression protein levels involved in autophagy proccess (P62, LC3B), antioxidative activity (GPX, SOD1), lipid peroxidation (PLA2G6) and lisosomal dynamic (LAMP1). Drugs screening allowed to select several drugs which reduced intracellular iron levels. With this technique we did another screening combining that drugs to select the best combination.

REFERENCES

Álvarez-Córdoba M, Fernández Khoury A, Villanueva-Paz M, Gómez-Navarro C, Villalón-García I, Suárez-Rivero JM, et al. Pantothenate Rescues Iron Accumulation in Pantothenate Kinase-Associated Neurodegeneration Depending on the Type of Mutation. Mol Neurobiol. 2018;

Furukawa Y, Kaneko K, Yamanaka K, O'Halloran T V., Nukina N. Complete loss of post-translational modifications triggers fibrillar aggregation of SOD1 in the familial form of amyotrophic lateral sclerosis. J Biol Chem. 2008;283(35):24167–76.

Petillon C, Hergesheimer R, Puy H, Corcia P, Vourc'h P, Andres C, et al. The Relevancy of Data Regarding the Metabolism of Iron to Our Understanding of Deregulated Mechanisms in ALS; Hypotheses and Pitfalls. Front Neurosci [Internet]. 2019;12(January):1–10.

